Showing 21-30 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Non-invasive immunoimaging of islet transplant rejection | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-June-2023 to 31-May-2027 | $750.000,00 |
| Novel Cell-free DNA and RNA Dynamics in Islet Transplant | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-August-2026 to 31-July-2028 | $600.000,00 |
| Pilot Clinical Trial of Allogenic Islet Transplantation under the Abdominal Anterior Rectus Sheath for Advancing Treatment of Type 1 Diabetes | Beckman Research Institute of the City of Hope | Fouad Kandeel | Cures | 01-October-2026 to 30-September-2028 | $800.000,00 |
| Do Islet Somatic Mutations Contribute to T1D Age at Onset? | Beckman Research Institute of the City of Hope | Melanie Shapiro | Cures | 01-March-2026 to 28-February-2027 | $100.000,00 |
| Clinical Trial of Denosumab for Type 1 Diabetes | Beckman Research Institute of the City of Hope | Rupangi Vasavada | Cures | 01-October-2023 to 30-November-2027 | $2.232.400,00 |
| Platforms for Cross-Therapeutic Profiling and Mechanistic Studies of Immune-Modifying Therapies in Type 1 Diabetes | Benaroya Research Institute at Virginia Mason | Dan Campbell | Cures | 01-March-2026 to 28-February-2029 | $1.045.621,50 |
| Assessing and mitigating T cell recognition of iPSC derived endocrine cells in Type 1 Diabetes | Benaroya Research Institute at Virginia Mason | Eddie James | Cures | 01-June-2024 to 31-December-2026 | $500.000,00 |
| Evaluating tissue transglutaminase as a treatment axis for T1D and beta cell replacement | Benaroya Research Institute at Virginia Mason | Eddie James | Cures | 01-June-2026 to 31-May-2029 | $1.050.000,00 |
| Cooperative harmonization and validation of an islet-specific AIM assay | Benaroya Research Institute at Virginia Mason | Karen Cerosaletti | Cures | 01-February-2024 to 31-January-2027 | $299.998,00 |
| New lipid biomarker to predict early risk for Type 1 diabetes | Beth Israel Deaconess Medical Center Inc | Barbara Kahn | Cures | 01-September-2024 to 31-August-2027 | $899.997,53 |